Dr. Jeffrey Dlott, Medical Director, Consumer Health at Quest Diagnostics discusses the company’s new virtual preventive care service called the Comprehensive Health Profile designed to meet the needs of individuals who want more visibility into their own health information and access to preventive care at their fingertips. The QuestDirect offering includes lab tests, a behavioral risk assessment, weight, blood pressure, and other information that will provide individuals a personalized snapshot of their overall health.
Author: healthprofessionalradio
Meditation for Back Health
Returning guest, Dr. Ken Hansraj, MD, a New York based spinal and orthopedic surgeon discusses “LIFT: Meditations To Boost Back Health” a six-track CD inspired by his daily meditations to treat his own chronic pain.
Tryp Therapeutics – Psychedelic Therapy Beyond Mental Health Care
Jim Gilligan, President and Chief Scientific Officer discusses Tryp Therapeutics, a pharmaceutical company focused on developing psilocybin-based compounds to treat diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s unique Psilocybin-For-Neuropsychiatric Disorders (PFN™) program focuses on developing synthetic psilocybin as a new class of drug for the treatment of chronic pain and other indications. Tryp Therapeutics brings a proprietary and differentiated approach to manufacturing, formulating, dosing, and administering psychedelic compounds, including advancing its novel compound TRP-8803 through preclinical trials with the aim to improve the patient experience and enhance patient safety.
UCB Partnership with NextSense in Seizure Detection Research
Colin Lake, Vice President of Digital Business Transformation for Neurology at UCB, discusses the company’s approach to digital solutions and how they complement UCB’s medicines for people living with epilepsy. He’ll spend time discussing a new collaboration with NextSense, a data platform and research on detecting seizures with biosensing earbuds that can be worn comfortably at night and as needed throughout the day.
The Development of New Therapies that Supplement Vaccines to Aid Vulnerable Communities
Dr. Dorry Segev, Professor of Surgery and Epidemiology and Associate Vice Chair of Surgery at Johns Hopkins University discusses the impact of COVID on the immunocompromised community and the importance of bringing new therapies to patients that supplement vaccines and provide long-lasting protection, including the FDA’s recent decision to authorize AstraZeneca’s COVID long-acting antibody (LAAB) combination named Evusheld (AZD7442), which can provide at least six months of protection against COVID-19 after a single dose. The emergency use authorization of Evusheld is an important step forward for people who may remain vulnerable to COVID-19 because of an inadequate response to a COVID-19 vaccine, including people with blood cancers or other cancers being treated with chemotherapy, and those taking medications after an organ transplant or who are taking immunosuppressive drugs for conditions including multiple sclerosis and rheumatoid arthritis.
Alliance for Endometriosis Survey Findings and Action Plan
Beth Battaglino, RN-C and CEO of HealthyWomen discusses a recent national public survey by The Alliance for Endometriosis which revealed that 90% of people with endometriosis are disbelieved, dismissed, or ignored by others at least monthly. The survey sheds light on people’s experiences with endometriosis-related stigma and the disconnect in conversations between patients and their health care providers. The Alliance for Endometriosis has created an Action Plan with the goal of reducing – or eliminating – the stigma associated with endometriosis and encouraging more productive patient and physician conversations that lead to faster diagnoses and improved treatment options and experiences.
ASH 2021 – AbbVie VENCLEXTA Data
Dr. Jalaja Potluri, Executive Medical Director at AbbVie and the Development Leader for VENCLEXTA (venetoclax) discusses data on VENCLEXTA reinforcing the efficacy and versatility of this treatment in numerous blood cancers, including acute myeloid leukemia (AML)(abstract 1271), myelodysplastic syndrome (MDS)(abstract 537), and chronic lymphocytic leukemia (CLL). These data were presented at the 2021 American Society of Hematology (ASH) Annual Meeting. Visit www.hematology.org to learn more.
Vituity Launches Personalized Care Navigation Startup Utilizing AI and Machine Learning
Andrew Smith, Chief Operations and Innovation Officer at Vituity and President of Inflect Health discusses the launch of Healthful, one of the first proprietary patient navigation platforms that leverage AI and machine learning to accurately and proactively identify patients who will benefit most from high touch care navigation. He talks about the benefits of Healthful’s approach to patient navigation to produce a holistic healthcare journey; addressing variables like transportation and scheduling that impact patients’ access to care.
Perspectives From a Leading Alzheimer’s Disease Researcher
Dr. David Henley, MD, Executive Medical Director, Alzheimer’s Disease Global Medical Affairs, Neurology Business Group at Eisai Inc. shares his perspective on recent advances in Alzheimer’s Disease research and therapeutic approaches including the role of the amyloid-beta pathway.
Diabetes Patient Success Story – Managing Your Diagnosis Through Collaborative Treatment and Proper Diet
In this segment, Ms. Jean Ford a 78-year-old diabetic and cancer survivor discusses the challenges she faced from her type-II diabetes as well as the treatment plan and education she received from the doctors at Weill Cornell Medicine that enabled her to live a medication-free lifestyle.